In a 15-month prospective study...
LUMASON® ultrasound enhancing agent was administered 2,137 times with no reports of back pain.1*
In pivotal trials…
Most adverse reactions were mild to moderate in intensity and resolved spontaneously.2
LUMASON STUDY RESULTS1
2,137
Doses
15
Months
0
Reports of Back Pain
* Based on a single-center study of adult patients (age >18 years) receiving a UEA (LUMASON®, Optison™, or Definity®) were prospectively evaluated for clinically significant adverse events defined as either anaphylactoid reactions (rash, flank pain, dyspnea, and wheeze) or true anaphylaxis. Study objectives included the following: determining the major adverse reactions experienced by patients receiving UEA in a clinical setting, assessing whether microbubbles are safe for use in patients with intra-cardiac shunts, and assessing whether the types of adverse reactions differ significantly among the three FDA-approved UEAs.
Learn more today!
Contact your LUMASON Account Manager to learn more about our multiple indications and our safety
